AgeX Therapeutics, a biotechnology company, agreed to merge with Serina Therapeutics, a clinical-stage biotechnology company. Financial terms were not disclosed. “We are delighted to announce the proposed merger with Serina. The AgeX team thoroughly reviewed and evaluated numerous strategic alternatives for creating stockholder value, and we believe this transaction with Serina presented the most compelling option for our stockholders. We see exciting potential to generate novel drug candidates with the POZ Platform delivery technology,” Joanne M. Hackett, AgeX Chairperson and Interim CEO.